Compare Noble Corporation plc (NE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Tango Therapeutics Inc. — how do they compare? Noble Corporation plc trades at $42.9 (market cap $6.85B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Noble Corporation plc is the larger of the two by market cap, and Noble Corporation plc pays a 4.66% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 27 Days and Tango Therapeutics Inc. for 0 Days on average.
| NE | TNGX | |
|---|---|---|
Market Cap | $6.85B | $3.74B |
Volume | 984,361 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $54.37 | $32.90 |
52-Week Low | $27.45 | $7.50 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $8.28B | $2.76B |
Dividend Yield | 4.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $43.42, up 1.12% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income falling to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though investor sentiment is tempered by an ongoing legal investigation and inconsistent quarterly earnings performance.
Outlook remains cautious with analyst consensus price target of $52 offering 20% upside potential, but risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. The stock presents moderate opportunity for value investors given reasonable valuation multiples, but requires careful monitoring of contract execution and resolution of legal matters.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
